Clinical Trial Details

A Prospective Registry to Cure Triple-Negative Breast Cancer in Patients with Early-Stage or Newly Diagnosed Metastatic Disease: The TNBC Registry (DF/HCC 18-617)

This is a prospective, multi-institutional registry of patients with newly diagnosed Triple Negative Breast Cancer (Stage I-IV). Our goal is to collect clinical data, tissue samples, blood samples, stool samples, and patient-reported data over the course of a patient’s treatment and follow-up. We aim to provide clinicians and scientists a comprehensive platform of biospecimens and data to ultimately promote and facilitate innovative future research.

Principal Investigator(s)

Steve Lo, MD


Dana-Farber Cancer Institute


Mary Miller, LPN at 203-358-8879 or [email protected]


Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.